Executive Management Archives

Ben Austin, CPA

Director of Finance

Ben has over 10 years of finance and accounting experience for early-stage and high-growth companies, primarily in the medical device…

David Youngberg

Senior Vice President, Sales

Dave Youngberg joins the SPR Therapeutics team with over 25 years of experience in the medical device and pharmaceutical industry,…

Mark Stultz

Senior Vice President, Market Development

Mark has been actively involved in health care and medical device market development for over 25 years having held senior…

Joseph Boggs Ph.D

Senior Vice President, Research and Development

Dr. Boggs has experience developing an R&D pipeline of patented technologies with competitive advantages to deliver safe and effective neuromodulation…

Maria E. Bennett

President, CEO and Founder

Maria (Walker) Bennett has led SPR Therapeutics since its inception. Prior to the formation of SPR, Ms. Bennett served as…

The SPRINT PNS System is indicated for up to 60 days in the back and/or extremities for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the craniofacial region. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT^® PNS System, MicroLead^™, OnePass Introducer^™, Rethink Your Pain Strategy^™, Outsmart Pain^™, Sustained Pain Relief Starts Here^™, Life. Get Back to It.^™ and SPR^® are registered or common law trademarks of SPR Therapeutics, Inc.